Atea Pharmaceuticals (AVIR) Interest & Investment Income (2019 - 2026)

Atea Pharmaceuticals' Interest & Investment Income history runs 8 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• In Q1 2026, Interest & Investment Income fell 47.35% year-over-year to $2.6 million; the TTM figure through Mar 2026 stood at $14.0 million (down 40.57% YoY), while the FY2025 annual figure was $16.4 million, down 35.76% from the prior year.
• Interest & Investment Income was $2.6 million for Q1 2026 at Atea Pharmaceuticals, down from $3.3 million in the prior quarter.
• In the past five years, Interest & Investment Income ranged from a high of $7.9 million in Q3 2023 to a low of $98000.0 in Q1 2022.
• Historically, Interest & Investment Income has averaged $5.0 million across 5 years, with a median of $5.6 million in 2022.
• The sharpest annual moves came in 2022 and 2026: Interest & Investment Income jumped 10862.75% in 2022, then tumbled 47.35% in 2026.
• A 5-year view of Interest & Investment Income shows it stood at $5.6 million in 2022, then surged by 38.76% to $7.8 million in 2023, then declined by 26.42% to $5.7 million in 2024, then plunged by 42.2% to $3.3 million in 2025, then slipped by 20.64% to $2.6 million in 2026.
• The last three Interest & Investment Income figures came in at $2.6 million (Q1 2026), $3.3 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.